IAM
BCTX

Iridian Asset Management’s Briacell Therapeutics BCTX Stock Holding History

Iridian Asset Management’s Portfolio BCTX Stock Details BCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$272K Buy
+65,000
New +$303K 0.11% 41

Other funds holding BCTX

CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
LCM
LuminArx Capital Management New York $136M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
AF
Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Iridian Asset Management's BCTX Position: Q1 2026 in Review

Iridian Asset Management opened a new position in Briacell Therapeutics (BCTX) in Q1 2026: 65,000 shares worth $272K. The stake represents 0.11% of the portfolio and ranks #41 among its holdings.

16 funds tracked by Wall St. Rank hold BCTX as of Q1 2026.

  • Iridian Asset Management held 65,000 shares of Briacell Therapeutics worth $272K as of Q1 2026.
  • Briacell Therapeutics was a new Iridian Asset Management position in Q1 2026.
  • Briacell Therapeutics made up 0.11% of Iridian Asset Management's portfolio in Q1 2026, its #41 holding.
  • 16 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q1 2026.

Based on Iridian Asset Management's 13F filing for Q1 2026, filed 24 Apr 2026.